Comparative Pharmacology
Head-to-head clinical analysis: VERICIGUAT versus VERQUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VERICIGUAT versus VERQUVO.
VERICIGUAT vs VERQUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vericiguat is a soluble guanylate cyclase (sGC) stimulator. It directly stimulates sGC, enhancing the sensitivity of sGC to endogenous nitric oxide (NO), thereby increasing cyclic guanosine monophosphate (cGMP) production. This leads to smooth muscle relaxation, vasodilation, and inhibition of vascular remodeling and fibrosis.
Vericiguat stimulates soluble guanylate cyclase (sGC) directly and independently of nitric oxide (NO), increasing cyclic guanosine monophosphate (cGMP) production, leading to smooth muscle relaxation, vasodilation, and inhibition of platelet aggregation and vascular remodeling.
1.25 mg orally three times daily with food; increase in 1.25 mg increments every 2 weeks as tolerated to target maintenance dose of 2.5 mg three times daily.
Initial: 10 mg orally once daily; after 2 weeks, titrate to 20 mg once daily, then to 40 mg once daily as tolerated. Maximum: 40 mg once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 4-5 hours in patients with chronic heart failure, allowing twice-daily dosing. In severe renal impairment, half-life may be prolonged (up to 8 hours).
Terminal elimination half-life is approximately 22 hours (range 18-26 h), supporting once-daily dosing. Steady-state reached within 5 days.
Vericiguat is eliminated primarily via non-renal routes, with approximately 53% of the dose recovered in feces and 40% in urine. Renal excretion of unchanged drug is minimal (<5% of the dose).
Renal elimination accounts for approximately 70% of total clearance, with 30% excreted unchanged in urine; biliary/fecal elimination accounts for ~30% primarily as metabolites.
Category C
Category C
Guanylate Cyclase Stimulator
Guanylate Cyclase Stimulator